First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti–PD-L1 Antibody ZKAB001

Yan Zhou, Qingcheng Yang, Yang Dong, Tong Ji, Bing Zhang, Cheng Yang, Shuier Zheng, Lina Tang, Chenliang Zhou, Guowei Qian, Yujing Huang, Wenxi Yu, Hongtao Li, Yonggang Wang, Aina He, Zan Shen, Qiyuan Bao, Yingqi Hua, Hongyu Bai, Jiayi Zhao, Xiaoyi Li, Xiangrong Dai, Jianjun Zhang, Haiyan Hu, Yang YaoClinical 2022 · DOI

Abstract

Switching to maintenance using ZKAB001 showed an acceptable safety profile and provided preliminary evidence of clinical activity in localized patients with osteosarcoma.
BibTeX
@inproceedings{zhou2022first,
  author = {Yan Zhou and Qingcheng Yang and Yang Dong and Tong Ji and Bing Zhang and Cheng Yang and Shuier Zheng and Lina Tang and Chenliang Zhou and Guowei Qian and Yujing Huang and Wenxi Yu and Hongtao Li and Yonggang Wang and Aina He and Zan Shen and Qiyuan Bao and Yingqi Hua and Hongyu Bai and Jiayi Zhao and Xiaoyi Li and Xiangrong Dai and Jianjun Zhang and Haiyan Hu and Yang Yao},
  title = {{First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti–PD-L1 Antibody ZKAB001}},
  booktitle = {Clinical},
  year = {2022},
  doi = {10.1158/1078-0432.ccr-22-2470},
}

Loading related content...

Figure